Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | EYA2 | O00167 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL144663 | 0.97 | KDM4E (0.68) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL18983963 | 0.97 | KDM4E (0.68) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL1478010 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL413600 | 0.94 | KDM4E (0.65) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL5193980 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL16990444 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL1477452 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL243998 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Edetic Acid SCHEMBL22654038 | 0.94 | KDM4E (0.65) | KDM4EALOX15MAPTSMN1; SMN2TDP1 | |
| Pentetic Acid SCHEMBL8765357 | 0.94 | KDM4E (0.73) | KDM4EALOX15MAPTSMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8729010-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8623833-B2 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | KAI PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | CELLGATE, INC., A DELAWARE CORPORATION | 2013-04-18 | — | — | US | disclosed |
| US-8278264-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110206610-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070173436-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | CELLGATE, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-7229961-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-6759387-B2 | DELIVERY ENHANCING TRANSPORTER THAT HAS SUFFICIENT GUANIDINO OR AMIDINO SIDECHAIN MOIETIES TO ENHANCE DELIVERY OF A COMPOUND CONJUGATED TO THE REAGENT ACROSS ONE OR MORE LAYERS OF THE TISSUE | CELLGATE, INC. | 2004-07-06 | — | — | US | disclosed |
| US-6730293-B1 | GLUCOCORTICOID, CYCLOSPORIN, FK506 OR ASCOMYCIN, CONJUGATE AND ARGININE RESIDUE TRANSPORTER; ENHANCING DRUG DELIVERY | CELLGATE, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6669951-B2 | Using conjugate comprising the compound and a delivery-enhancing transporter wherein the compound is attached to the delivery-enhancing transporter through a linker comprising at least 5 guanidino or amidino moieties | CELLGATE, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030083256-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | CELLGATE, INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030022831-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | CELLGATE, INC., A DELAWARE CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-20020127198-A1 | Using conjugate comprising the compound and a delivery-enhancing transporter wherein the compound is attached to the delivery-enhancing transporter through a linker comprising at least 5 guanidino or amidino moieties | KAI PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213277-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | SLC7A1, ADM2, ARG1 | KDM4E 1210/4885ALOX15 2576/4885MAPT 848/4885 |
| US-20140213532-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | ADM2, SLC7A1, ARG1 | KDM4E 2245/4885ALOX15 2765/4885MAPT 1214/4885 |
| US-20130096069-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO OCULAR TISSUES | SLC7A1, ADM2, ARG1 | KDM4E 1210/4885ALOX15 2576/4885MAPT 848/4885 |
| US-20110206610-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | SLC7A1, ADM2, ARG1 | KDM4E 1824/4885ALOX15 2294/4885MAPT 1141/4885 |
| US-20070173436-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | SLC7A1, ADM2, ARG1 | KDM4E 1824/4885ALOX15 2294/4885MAPT 1141/4885 |
| US-20030083256-A1 | Compositions and methods for enhancing drug delivery across and into epithelial tissues | ADM2, SLC7A1, PGF | KDM4E 1441/4885ALOX15 2434/4885MAPT 1127/4885 |
| US-20020127198-A1 | Using conjugate comprising the compound and a delivery-enhancing transporter wherein the compound is attached to the delivery-enhancing transporter through a linker comprising at least 5 guanidino or amidino moieties | SLC7A1, SLC1A5, SLC43A1 | KDM4E 1502/4885ALOX15 3090/4885MAPT 714/4885 |
| US-20030022831-A1 | Compositions and methods for enhancing drug delivery across and into ocular tissues | SLC7A1, ADM2, ARG1 | KDM4E 1210/4885ALOX15 2576/4885MAPT 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.